Page last updated: 2024-08-24

triazoles and Cystadenocarcinoma, Serous

triazoles has been researched along with Cystadenocarcinoma, Serous in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Armstrong, DK; Bergstrom, J; DeBernardo, R; Fader, AN; Gaillard, S; Jernigan, A; Levinson, KL; Michener, C; Ricci, S; Roche, KL; Rose, PG; Shih, IM; Stone, RL; Tanner, EJ; Wang, TL; Wethingon, S; Yang, B; Zhang, G	1
Friedlander, M; Heinzelmann-Schwarz, V; Jacob, F; Knipprath Mészaros, A; Russell, K; Schoetzau, A; Singer, G; Stadlmann, S; Vetter, M	1
Figg, WD; Hussain, MM; Kohn, EC; Kotz, H; Minasian, L; Oliver, VK; Premkumar, A; Raggio, M; Reed, E; Sarosy, G; Steinberg, SM; Zhai, S	1

Trials

1 trial(s) available for triazoles and Cystadenocarcinoma, Serous

Article	Year
Phase II trial of carboxyamidotriazole in patients with relapsed epithelial ovarian cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Dec-01, Volume: 21, Issue:23 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Calcium Channel Blockers; Carcinoma, Endometrioid; Carcinoma, Papillary; Cystadenocarcinoma, Serous; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Salvage Therapy; Survival Rate; Treatment Outcome; Triazoles	2003

Article

Year

Phase II trial of carboxyamidotriazole in patients with relapsed epithelial ovarian cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Dec-01, Volume: 21, Issue:23

Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Calcium Channel Blockers; Carcinoma, Endometrioid; Carcinoma, Papillary; Cystadenocarcinoma, Serous; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Salvage Therapy; Survival Rate; Treatment Outcome; Triazoles

2003

Other Studies

2 other study(ies) available for triazoles and Cystadenocarcinoma, Serous

Article	Year
Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival? Gynecologic oncology, 2017, Volume: 147, Issue:1 Topics: Adult; Aged; Anastrozole; Antineoplastic Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; Cystadenocarcinoma, Serous; Cytoreduction Surgical Procedures; Female; Humans; Letrozole; Medical Overuse; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Ovarian Neoplasms; Retrospective Studies; Survival Analysis; Tamoxifen; Triazoles	2017
Letrozole may be a valuable maintenance treatment in high-grade serous ovarian cancer patients. Gynecologic oncology, 2018, Volume: 148, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Cohort Studies; Cystadenocarcinoma, Serous; Datasets as Topic; Disease-Free Survival; Estrogen Receptor alpha; Female; Humans; Immunohistochemistry; Letrozole; Maintenance Chemotherapy; Middle Aged; Nitriles; Ovarian Neoplasms; Triazoles; Young Adult	2018

Article

Year

Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?

Gynecologic oncology, 2017, Volume: 147, Issue:1

Topics: Adult; Aged; Anastrozole; Antineoplastic Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; Cystadenocarcinoma, Serous; Cytoreduction Surgical Procedures; Female; Humans; Letrozole; Medical Overuse; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Ovarian Neoplasms; Retrospective Studies; Survival Analysis; Tamoxifen; Triazoles

2017

Letrozole may be a valuable maintenance treatment in high-grade serous ovarian cancer patients.

Gynecologic oncology, 2018, Volume: 148, Issue:1

Topics: Adult; Aged; Antineoplastic Agents; Cohort Studies; Cystadenocarcinoma, Serous; Datasets as Topic; Disease-Free Survival; Estrogen Receptor alpha; Female; Humans; Immunohistochemistry; Letrozole; Maintenance Chemotherapy; Middle Aged; Nitriles; Ovarian Neoplasms; Triazoles; Young Adult

2018